Biweekly personal health coaching
10.1016/j.lfs.2004.04.038 79
Recent major deals Roche & Zealand Pharma: a $5.3 billion partnership to develop an amylin analog - a next generation treatment targeting appetite regulation AbbVie & Gubra: a $350 million licensing deal for an experimental obesity therapy, likely with multi-receptor or novel pathway targeting These deals highlight a significant shift in research strategy Rather than relying solely on internal R&D or acquisitions, pharma companies are leveraging biotech partnerships to accelerate innovation
These antidiabetic agents increase the glucose-dependent secretion of insulin from functioning beta cells, decrease glucagon release after meals, decrease hepatic glucose production, delayed gastric emptying, suppress the appetite and promotes beta cell proliferation
Of course, these are things all of us should be doing, whether were on a GLP-1, trying to lose weight without medications or just trying to live our healthiest lives.
-1775582746855.png&w=384&q=75)
